Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2024-12-19 Major Shareholding Noti…
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding ('Antal aktier', 'Andel') for a specific instrument (Shares SE0008241491) involving a holder ('Colombus International Holdings, Inc.') and an issuer ('SynAct Pharma AB'). The transaction reason is listed as 'Sälj' (Sell), and the resulting holding percentage (9.90908%) crosses or is near a threshold (10%). This structure is characteristic of mandatory notifications regarding changes in significant ownership stakes, which corresponds to the Major Shareholding Notification category.
2024-12-19 Swedish
SynAct Pharma AB announces outcome of the directed share issues
Capital/Financing Update Classification · 98% confidence The document is titled "SynAct Pharma AB announces outcome of the directed share issues" and details the completion of a directed share issue, including the number of shares issued (5,191,003), the subscription price (8.65 SEK), the resulting increase in share capital, and the expected first day of trading. This content directly relates to a capital raising or financing activity. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it is a press release announcing the outcome, the core subject matter is the financing event itself, making CAP more specific than a general RPA or RNS. The document length is substantial (nearly 10,000 characters), suggesting it is the primary announcement, not just a brief notification of publication.
2024-12-17 English
SynAct Pharma AB offentliggör utfall av de riktade nyemissionerna av aktier
Capital/Financing Update Classification · 98% confidence The document is a press release from SynAct Pharma AB announcing the outcome ('utfall') of directed share issues ('riktade nyemissionerna'). It details the number of shares issued (5,191,003), the subscription price (8.65 SEK), the resulting increase in share capital, and the planned first day of trading for the new shares. This activity directly relates to fundraising, financing activities, and changes in the capital structure. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it is a press release, the core content is the completion of a financing event, making CAP more specific than a general RPA or RNS.
2024-12-17 Swedish
SynAct Pharma AB offentliggör prospekt med anledning av upptagande till handel av nyemitterade aktier på Nasdaq Stockholm
Report Publication Announcement Classification · 100% confidence The document is a press release from SynAct Pharma AB announcing the publication and registration of a prospectus with the Swedish Financial Supervisory Authority (Finansinspektionen) regarding the admission to trading of newly issued shares. Following the 'Menu vs Meal' rule, this document is an announcement about the availability of a report (the prospectus) rather than the prospectus itself. Therefore, it is classified as a Report Publication Announcement (RPA).
2024-12-17 Swedish
SynAct Pharma AB publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm
Report Publication Announcement Classification · 100% confidence The document is a press release announcing the publication and registration of a prospectus for the admission of new shares to trading on Nasdaq Stockholm. It explicitly states that the prospectus is available on the company's website and provides a link to the document. Following the 'Menu vs Meal' rule, since this is an announcement about the availability of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2024-12-17 English
Bulletin from the extraordinary general meeting of SynAct Pharma AB
AGM Information Classification · 99% confidence The document is explicitly titled "Bulletin from the extraordinary general meeting of SynAct Pharma AB" and details resolutions passed at this meeting, specifically concerning directed share issues, a rights issue, and authorization for future share issuance. These resolutions directly relate to corporate governance and shareholder decisions made during a general meeting. While it involves share capital changes (CAP/SHA), the primary context is the outcome of the shareholder meeting. The closest fit among the provided codes is AGM-R (AGM Information), as an Extraordinary General Meeting (EGM) bulletin serves a similar function to AGM materials, summarizing key decisions made by shareholders. It is not a standard regulatory filing like 10-K or ER, nor is it solely a proxy solicitation (PSI) or a simple announcement of a report (RPA).
2024-12-13 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.